00512 GRANDPHARMA
- 4.460
- +0.120+2.76%
GRANDPHARMA News
Yuanda Pharmaceutical (00512.HK): Revenue increased 15% in the first half of the year and has formed a good echelon effect in the research pipeline
First Shanghai Securities: Maintaining Yuanda Pharmaceutical's (00152) “Buy” Rated Heavy Product Yttrium to be Listed in 2022
Yuanda Pharmaceutical (0512.HK): Strengthening the leading position in the amino acid sector and expanding high-value-added downstream business
Yuanda Pharmaceutical (0512.HK): The blockbuster product Yttrium 90 was launched this year, actively and rapidly laying out innovative product pipelines
Yuanda Pharmaceutical (0512.HK): The blockbuster product Yttrium 90 was launched this year, actively and rapidly laying out innovative product pipelines
Yuanda Pharmaceutical (0512.HK): Rapid growth in performance, innovative drugs and devices have entered a harvest period
Yuanda Pharmaceutical (00512.HK): Core business advantages, stable innovation pipeline ushered in a harvest period
Yuanda Pharmaceutical (0512.HK): Heavy nuclear drug product Y90 resin microspheres approved
Yuanda Pharmaceutical (0512.HK): Accelerating Transformation, Innovation, Commercialization and Implementation
Yuanda Pharmaceutical (0512.HK): A number of innovative products are about to be relaunched, global cooperation accelerates the process of internationalization
Yuanda Pharmaceutical (0512.HK): Continued rapid growth in performance and in-depth deployment of innovative drugs and devices
Yuanda Pharmaceutical (0512.HK) 2021 First Half Results Announcement Comment: International Layout Accelerates Long-term Equity Incentives Firmly Confidence in Development
Yuanda Pharmaceutical (00512.HK): Innovative products will soon blossom more and harvest can be expected
Yuanda Pharmaceutical (00512.HK) 2020 Annual Report Review: Performance Exceeds Expectations, Innovation Investment Continues to Increase
Yuanda Pharmaceutical (0512.HK): Profit growth exceeds expectations, innovative medical device research and development is progressing smoothly
Yuanda Pharmaceutical (0512.HK): Introduction and Implementation+Independent R&D Accelerates International Development
Yuanda Pharmaceutical (00512.HK): Stable performance and innovative business in traditional areas of advantage can be expected in the future
Yuanda Pharmaceutical (00512.HK): Thinner hair has a long way to go
Yuanda Pharmaceutical (0512.HK): Continued development in the field of tumor diagnosis and treatment, product structure optimization can be expected
Yuanda Pharmaceutical (00512.HK): Sales will improve in the second half of the year and the product structure will continue to be optimized
Analysis
Price Target
No Data
